Lineage Cell Therapeutics
LCTX
58 hedge funds and large institutions have $57.7M invested in Lineage Cell Therapeutics in 2014 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 20 increasing their positions, 13 reducing their positions, and 6 closing their positions.
54% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 13
1.14% more ownership
Funds ownership: 31.19% → 32.33% (+1.1%)
0% more funds holding
Funds holding: 58 → 58 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 6
5% less capital invested
Capital invested by funds: $60.9M → $57.7M (-$3.22M)
82% less call options, than puts
Call options by funds: $27K | Put options by funds: $152K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$1.82M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$787K |
| 3 |
Morgan Stanley
New York
|
+$577K |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$446K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$374K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.21M |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$255K |
| 3 |
Group One Trading
Chicago,
Illinois
|
-$132K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$130K |
| 5 |
D.E. Shaw & Co
New York
|
-$104K |
LCTX Hedge Fund Activity: Q1 2014 in Review
58 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q1 2014, worth a combined $57.7M — down 5.3% from $60.9M a quarter earlier.
Fund positioning in LCTX was balanced in Q1 2014: 6 funds opened new positions, 6 closed out, 20 added to existing stakes and 13 trimmed.
The largest buyer was Broadwood Capital, adding an estimated $1.82M. The largest seller was Fidelity Investments, exiting entirely with an estimated $2.21M sold.
- 58 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q1 2014, unchanged from Q4 2013.
- Funds reported $57.7M of Lineage Cell Therapeutics stock for Q1 2014, down 5.3% quarter-over-quarter.
- 6 funds opened new Lineage Cell Therapeutics positions in Q1 2014 and 6 closed out, a net change of 0 holders.
- The largest Lineage Cell Therapeutics buyer in Q1 2014 was Broadwood Capital, an estimated $1.82M added.
- The largest Lineage Cell Therapeutics seller in Q1 2014 was Fidelity Investments, an estimated $2.21M sold.
Based on aggregated 13F filings for Q1 2014.